RxDoctor Payments Data

Amanda Pummill

Family · Lebanon, OHNPI 1801147020

Payments from drug & device makers

$2,085in general payments, 2019–2025

Across 68 payments — averaging $30.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$640
  • AstraZeneca$594
  • Novo Nordisk$245
  • AbbVie$222
  • Astellas Pharma US Inc$130
  • Bayer$122
  • plus $132 from 4 others

What the payments were for

  • Food & beverage$1,98595%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,085 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$15,792
Medicare patients
58
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$61,256
TrulicityDulaglutide18$32,527
JardianceEmpagliflozin19$29,198
MounjaroTirzepatide11$19,451
FarxigaDapagliflozin Propanediol19$17,208
LinzessLinaclotide11$5,988
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,575
Humalog Kwikpen U-100Insulin Lispro16$2,338
Albuterol Sulfate HfaAlbuterol Sulfate39$1,102
Omeprazole71$982
Sucralfate12$876
Fluticasone Propionate38$801
Atorvastatin Calcium100$768
Sure Comfort Pen NeedlePen Needle, Diabetic12$731
Levothyroxine Sodium72$706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$245$61,25638 claims
Lilly USA, LLCTrulicity, Mounjaro$88$51,97829 claims
Boehringer IngelheimJardiance$13$29,19819 claims
AstraZenecaFarxiga, Bevespi Aerosphere$594$21,78330 claims
AbbVieLinzess$222$5,98811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Lebanon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →